Research programme: T cell therapeutics - Celgene/Juno TherapeuticsAlternative Names: Autoimmune disorder therapeutics - Celgene/Juno; Cancer therapeutics - Celgene/Juno; CAR T cell products - Celgene/Juno; Chimeric antigen receptor T lymphocytes - Celgene/Juno; TCR T cell products - Celgene/Juno
Latest Information Update: 16 Jul 2015
At a glance
- Originator Celgene Corporation; Juno Therapeutics
- Class CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunomodulators; Immunostimulants; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer